Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by Physico-chemical characteristics of the drug substance only.
In the last several years, the development of the Liposomes Drug Delivery market is fast with an average growth rate of 13.52%. In 2017, the global revenue of the Liposomes Drug Delivery market is nearly 2.30 billion USD.
In 2019, the global Liposome Drug Delivery market size was US$ 3350.6 million and is forecast to US$ 7856.2 million in 2026, growing at a CAGR of 12.8% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Liposome Drug Delivery.
Request Sample Report @ https://www.qyresearch.com/sample-form/form/1510645/global-liposome-drug-delivery-industry
Market Segmentation by Type and by Application
Market Segment by Type, the Liposome Drug Delivery market is segmented into
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
Market Segment by Application, the Liposome Drug Delivery market is segmented into
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Others
This report includes the following manufacturers;
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Johnson & Johnson
- Luye Pharma
- Sigma-Tau
- Ipsen (Onivyde)
- CSPC
- Teva Pharmaceutical
- Novartis
- Fudan-Zhangjiang
In this study, the years considered to estimate the market size of Liposome Drug Delivery are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
Buy Full Report , Report Price: USD 4,900 @ https://www.qyresearch.com/settlement/pre/96c10e1bf012dc38fb4364c236da5e9b,0,1,
